Monitoring immune responses in cancer patients receiving tumor vaccines

被引:26
作者
Walker, EB
Disis, MLN
机构
[1] Robert W Franz Canc Res Ctr, Earle A Chiles Res Inst, Providence Portland Med Ctr, Portland, OR 97213 USA
[2] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA
关键词
immunomonitoring assays; cancer vaccines;
D O I
10.1080/08830180305226
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Clinical evaluation of therapeutic tumor vaccines has resulted in examination and comparison of the types of immune function assays required to monitor tumor antigen-stimulated T cell effector function in immunized patients. Three of the most commonly used assays include ELISPOT, tetramer assay, and cytokine flow cytometry (CFC). Discussed are the method and principles for each assay and an assessment of important methodological, reagent, and data acquisition issues that are relevant for the accurate and effective use of the assays. The sensitivity and utility of the assays and present arguments advocating their integrated use in future immunomonitoring studies are also discussed.
引用
收藏
页码:283 / 319
页数:37
相关论文
共 140 条
[101]  
Ranieri Elena, 2000, Immunological Investigations, V29, P121, DOI 10.3109/08820130009062294
[102]   Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - A preliminary report [J].
Reinartz, S ;
Boerner, H ;
Koehler, S ;
Von Ruecker, A ;
Schlebusch, H ;
Wagner, U .
HYBRIDOMA, 1999, 18 (01) :41-45
[103]  
Reynolds SR, 1997, INT J CANCER, V72, P972
[104]   Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes [J].
Romero, P ;
Dunbar, PR ;
Valmori, D ;
Pittet, M ;
Ogg, GS ;
Rimoldi, D ;
Chen, JL ;
Liénard, D ;
Cerottini, JC ;
Cerundolo, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1641-1650
[105]  
Romero P, 2000, E SCHERING RES FDN W, V30, P75
[106]   Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life [J].
Rubio-Godoy, V ;
Dutoit, V ;
Rimoldi, D ;
Lienard, D ;
Lejeune, F ;
Speiser, D ;
Guillaume, P ;
Cerottini, JC ;
Romero, P ;
Valmori, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10302-10307
[107]   Regulatory T cells: Key controllers of immunologic self-tolerance [J].
Sakaguchi, S .
CELL, 2000, 101 (05) :455-458
[108]  
Salgaller ML, 1996, CANCER RES, V56, P4749
[109]   Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma [J].
Scheibenbogen, C ;
Schmittel, A ;
Keilholz, U ;
Allgäuer, T ;
Hofmann, U ;
Max, R ;
Thiel, E ;
Schadendorf, D .
JOURNAL OF IMMUNOTHERAPY, 2000, 23 (02) :275-281
[110]  
Scheibenbogen C, 1997, CLIN CANCER RES, V3, P221